Evidence map›Paper›PMID 34934826›Full record

ArticleBiochemistry and biophysics reports2021

Glycyrrhizin and its derivatives promote hepatic differentiation via sweet receptor, Wnt, and Notch signaling.

Akihiro Morita, Yuta Omoya, Rie Ito, Yuya Ishibashi, Keiichi Hiramoto, Shiho Ohnishi, Nobuji Yoshikawa, Shosuke Kawanishi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemistry and biophysics reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Akihiro MoritaDepartment of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie, 513-8670, Japan.
Yuta OmoyaDepartment of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie, 513-8670, Japan.
Rie ItoDepartment of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie, 513-8670, Japan.
Yuya IshibashiDepartment of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie, 513-8670, Japan.
Keiichi HiramotoDepartment of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie, 513-8670, Japan.
Shiho OhnishiDepartment of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie, 513-8670, Japan.
Nobuji YoshikawaMatsusaka R&D Center, Cokey Co., Ltd., Matsusaka, Mie, 515-0041, Japan.
Shosuke KawanishiDepartment of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie, 513-8670, Japan.
Suzuka University of Medical Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The acute liver disease is involved in aberrant release of high-mobility group box 1 (HMGB1). Glycyrrhizin (GL), a traditional Chinese medicine for liver disease, binds to HMGB1, thereby inhibits tissue injury. However the mode of action of GL for chronic liver disease remains unclear. We investigated the effects of glycyrrhizin (GL) and its derivatives on liver differentiation using human iPS cells by using a flow cytometric analysis. GL promoted hepatic differentiation at the hepatoblast formation stage. The GL derivatives, 3-

Indexed as

AFP, α-fetoproteinApi, 3-O-[apiosyl (1 → 2)-glucuronyl] βGACBX, carbenoxolone, 3-O-hemisuccinyl βGACK-19, cytokeratin 19DMSO, dimethyl sulfoxideDP, (±)-2-(2,4-dichlorophenoxy) propionic acidGlc, 3-O-[glucosyl (1 → 2)-glucuronyl] βGAGL, glycyrrhizinGlycyrrhizinHepatic differentiationHes, hairy and enhancer of splitHMGB1, high-mobility group box1HNF-4α, hepatocyte nuclear factor 4αLiver regenerationLSG, licorice saponin GLSH, licorice saponin HMono, 3-O-mono-glucuronyl βGASweet receptorT1R3αGA, 18α-glycyrrhetinic acidβGA, 18β-glycyrrhetinic acid

Identifiers

PMID34934826
PMCPMC8654616
OpenAlexW4200178472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.